分子机制与风湿性疾病新治疗概念
Molecular underpinnings of rheumatic diseases and emerging therapeutic concepts
该综述文章探讨了风湿性疾病中的分子机制,并介绍了新兴的治疗概念。研究表明,通过单细胞 RNA 测序分析可以将类风湿关节炎患者分为不同的疾病亚型,有助于指导个体化治疗。
Callahan, L. F. & Pincus, T. Mortality in the rheumatic diseases. Arthritis Rheum. 8, 229–241 (1995).
Gabriel, S. E. & Michaud, K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res. Ther. 11, 229 (2009).
Feldmann, M. Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. 2, 364–371 (2002).
Maini, R. N. & Taylor, P. C. Anti-cytokine therapy for rheumatoid arthritis. Annu. Rev. Med. 51, 207–229 (2000).
Weaver, A. L. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology 43, iii17–iii23 (2004).
Schett, G., McInnes, I. B. & Neurath, M. F. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N. Engl. J. Med. 385, 628–639 (2021).
McInnes, I. B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429–442 (2007).
Tanaka, Y., Luo, Y., O’Shea, J. J. & Nakayamada, S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat. Rev. Rheumatol. 18, 133–145 (2022).
Fleischmann, R. et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367, 495–507 (2012).
Van Vollenhoven, R. F. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508–519 (2012).
Schett, G., Tanaka, Y. & Isaacs, J. D. Why remission is not enough: underlying disease mechanisms in RA that prevent cure. Nat. Rev. Rheumatol. 17, 135–144 (2021).
Schett, G. et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann. Rheum. Dis. 75, 1428–1437 (2016).
Haschka, J. et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann. Rheum. Dis. 75, 45–51 (2016). This study demonstrates that tapering therapy results in frequent relapse of disease particularly in patients with ACPA-positive RA.
Aringer, M. et al. 2019 EULAR/ACR classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 71, 1400–1412 (2019).
Aletaha, D. et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62, 2569–2581 (2010).
Tanaka, H. et al. Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping. Ann. Rheum. Dis. 83, 242–252 (2024).
Zhang, F. et al. Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. Nature 623, 616–624 (2023). This study shows that single-cell RNA-sequencing-based phenotyping of synovial tissue enables stratification of patients with RA into different disease subtypes.
Robinson, G. A. et al. Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach. Lancet Rheumatol. 2, e485–e496 (2020).
Rivellese, F. & Pitzalis, C. Cellular and molecular diversity in rheumatoid arthritis. in Seminars in Immunology, Vol. 58 (eds Rivellese, F. et al.) 101519 (Elsevier, 2021).
Rivellese, F. et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat. Med. 28, 1256–1268 (2022).This trial demonstrates that molecular phenotyping of the synovial tissue ofpatients with RA enables prediction of therapeutic responses.
Rao, D. A. Immune-cell profiling to guide stratification and treatment of patients with rheumatic diseases. Nat. Rev. Rheumatol. 21, 657–670 (2025).
Rivellese, F. et al. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials. Lancet Rheumatol. 5, e648–e659 (2023).
Lewis, M. J. et al. Deep molecular profiling of synovial biopsies in the STRAP trial identifies signatures predictive of treatment response to biologic therapies in rheumatoid arthritis. Nat. Commun. 16, 5374 (2025).
Barturen, G., Beretta, L., Cervera, R., Van Vollenhoven, R. & Alarcón-Riquelme, M. E. Moving towards a molecular taxonomy of autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 14, 75–93 (2018).
Kirino, Y. & Remmers, E. F. Genetic architectures of seropositive and seronegative rheumatic diseases. Nat. Rev. Rheumatol. 11, 401–414 (2015).
Kuiper, J. J. et al. EULAR study group on ‘MHC-I-opathy’: identifying disease-overarching mechanisms across disciplines and borders. Ann. Rheum. Dis. 82, 887–896 (2023).
Buckley, C. D., Gilroy, D. W., Serhan, C. N., Stockinger, B. & Tak, P. P. The resolution of inflammation. Nat. Rev. Immunol. 13, 59–66 (2013).
Sparks, J. A. & Costenbader, K. H. Genetics, environment, and gene-environment interactions in the development of systemic rheumatic diseases. Rheum. Dis. Clin. North Am. 40, 637–657 (2014).
Clarke, A. & Vyse, T. J. Genetics of rheumatic disease. Arthritis Res. Ther. 11, 248 (2009).
Gough, S. C. L., Walker, L. S. K. & Sansom, D. M. CTLA4 gene polymorphism and autoimmunity. Immunol. Rev. 204, 102–115 (2005).
Serrano, N. C., Millan, P. & Páez, M.-C. Non-HLA associations with autoimmune diseases. Autoimmun. Rev. 5, 209–214 (2006).
Begovich, A. B. et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet. 75, 330–337 (2004).
Menard, L. et al. The PTPN22allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J. Clin. Invest. 121, 3635–3644 (2011).
Schickel, J.-N. et al. PTPN22 inhibition resets defective human central B cell tolerance. Sci. Immunol. 1, aaf7153 (2016).
Adrianto, I. et al. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat. Genet. 43, 253–258 (2011).
Li, W.-W. et al. Tyrosine phosphorylation of IRF3 by BLK facilitates its sufficient activation and innate antiviral response. PLoS Pathog. 19, e1011742 (2023).
Suzuki, A. et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat. Genet. 34, 395–402 (2003).
Al-Mayouf, S. M. et al. Loss-of-function variant in DNASE1L3causes a familial form of systemic lupus erythematosus. Nat. Genet. 43, 1186–1188 (2011).
Kuehn, H. S. et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 345, 1623–1627 (2014).
Trynka, G. et al. Chromatin marks identify critical cell types for fine mapping complex trait variants. Nat. Genet. 45, 124–130 (2013).
Farh, K. K.-H. et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518, 337–343 (2015). This study demonstrates that the majority of disease-associated genetic variants identified in patients with autoimmune disease can be mapped to immune-cell enhancers.
Calderon, D. et al. Landscape of stimulation-responsive chromatin across diverse human immune cells. Nat. Genet. 51, 1494–1505 (2019).
Dörner, T., Jacobi, A. M. & Lipsky, P. E. B cells in autoimmunity. Arthritis Res. Ther. 11, 247 (2009).
Kang, E. H., Ha, Y.-J. & Lee, Y. J. Autoantibody biomarkers in rheumatic diseases. Int. J. Mol. Sci. 21, 1382 (2020).
van Delft, M. A. M. & Huizinga, T. W. J. An overview of autoantibodies in rheumatoid arthritis. J. Autoimmun. 110, 102392 (2020).
Rubin, S. J., Bloom, M. S. & Robinson, W. H. B cell checkpoints in autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 15, 303–315 (2019).
Cabral-Marques, O. & Riemekasten, G. Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseases. Nat. Rev. Rheumatol. 13, 648–656 (2017).
Jiang, D., Lim, W., Crowther, M. & Garcia, D. A systematic review of the association between anti-β−2 glycoprotein I antibodies and APS manifestations. Blood Adv. 5, 3931–3936 (2021).
Ludwig, R. J. et al. Mechanisms of autoantibody-induced pathology. Front. Immunol. 8, 603 (2017).
Rao, D. A. et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature 542, 110–114 (2017).This study identifies an expanded population of potentially disease-relevant expanded population of PD-1hiCXCR5−CD4+ T cells in the inflamed synovial tissue from patients with RA.
Lin, J., Yu, Y., Ma, J., Ren, C. & Chen, W. PD-1+CXCR5−CD4+ T cells are correlated with the severity of systemic lupus erythematosus. Rheumatology 58, 2188–2192 (2019).
Donado, C. A. et al. Granzyme K activates the entire complement cascade. Nature 641, 211–221 (2025).This study shows that GZMK-expressing T cells drive complement activation in inflamed synovial tissue of patients with RA.
Malmström, V., Venalis, P. & Albrecht, I. T cells in myositis. Arthritis Res. Ther. 14, 230 (2012).
Scherer, H. U., Huizinga, T. W. J., Krönke, G., Schett, G. & Toes, R. E. M. The B cell response to citrullinated antigens in the development of rheumatoid arthritis. Nat. Rev. Rheumatol. 14, 157–169 (2018).
Natalini, J. G. et al. Autoantibody seropositivity and risk for interstitial lung disease in a prospective male-predominant rheumatoid arthritis cohort of U.S. veterans. Ann. Am. Thorac. Soc. 18, 598–605 (2021).
Betteridge, Z. & McHugh, N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J. Intern. Med. 280, 8–23 (2016).
Olsen, N. J. & Karp, D. R. Autoantibodies and SLE—the threshold for disease. Nat. Rev. Rheumatol. 10, 181–186 (2014).
Pisetsky, D. S. & Lipsky, P. E. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat. Rev. Rheumatol. 16, 565–579 (2020).
Lapteva, L. et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum. 54, 2505–2514 (2006).
Arbuckle, M. R. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526–1533 (2003). This study shows that emergence of anti-nuclear auto-antibodies precedes onset of SLE for several years.
van Zanten, A. et al. Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands. Ann. Rheum. Dis. 76, 1184–1190 (2017). This study shows that emergence of ACPAs can precede onset of RA for several years.
Pfeifle, R. et al. Regulation of autoantibody activity by the IL-23–TH17 axis determines the onset of autoimmune disease. Nat. Immunol. 18, 104–113 (2017). This study shows that pathogenic T cells can dictate the inflammatory activity of autoantibodies by instructing autoreactive B cells and regulating the extend of antibody glycosylation.
Lu, D. R. et al. T cell–dependent affinity maturation and innate immune pathways differentially drive autoreactive B cell responses in rheumatoid arthritis. Arthritis Rheumatol. 70, 1732–1744 (2018).
Hoi, A., Igel, T., Mok, C. C. & Arnaud, L. Systemic lupus erythematosus. Lancet 403, 2326–2338 (2024).
Postal, M. et al. Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr. Opin. Immunol. 67, 87–94 (2020).
Siegel, C. H. & Sammaritano, L. R. Systemic lupus erythematosus: a review. JAMA 331, 1480–1491 (2024).
Tsao, B. P. The genetics of human systemic lupus erythematosus. Trends Immunol. 24, 595–602 (2003).
Harley, J. B., Kelly, J. A. & Kaufman, K. M. Unraveling the genetics of systemic lupus erythematosus. Springer Semin. Immunopathol. 28, 119–130 (2006).
Brown, G. J. et al. TLR7gain-of-function genetic variation causes human lupus. Nature 605, 349–356 (2022).This study identifies hyperactive variants of TLR7 as major genetic drivers of SLE.
Wolf, C. et al. UNC93B1 variants underlie TLR7-dependent autoimmunity. Sci. Immunol. 9, eadi9769 (2024).
Majer, O., Liu, B., Kreuk, L. S. M., Krogan, N. & Barton, G. M. UNC93B1 recruits syntenin-1 to dampen TLR7 signalling and prevent autoimmunity. Nature 575, 366–370 (2019).
Muñoz, L. E., Lauber, K., Schiller, M., Manfredi, A. A. & Herrmann, M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat. Rev. Rheumatol. 6, 280–289 (2010).
Dörner, T. & Lipsky, P. E. The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus. Nat. Rev. Rheumatol. 20, 770–782 (2024).
Fillatreau, S., Manfroi, B. & Dörner, T. Toll-like receptor signalling in B cells during systemic lupus erythematosus. Nat. Rev. Rheumatol. 17, 98–108 (2021).
Sarkar, M. et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal derived interferon kappa. Ann. Rheum. Dis. 77, 1653–1664 (2018).
Farkas, L., Beiske, K., Lund-Johansen, F., Brandtzaeg, P. & Jahnsen, F. L. Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol. 159, 237–243 (2001).
Koffler, D., Agnello, V., Thoburn, R. & Kunkel, H. G. Systemic lupus erythematosus: prototype of immune complex nephritis in man. J. Exp. Med. 134, 169–179 (1971).
Savarese, E. et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 107, 3229–3234 (2006).
Lövgren, T., Eloranta, M.-L., Båve, U., Alm, G. V. & Rönnblom, L. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 50, 1861–1872 (2004).
Rodero, M. P. & Crow, Y. J. Type I interferon–mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview. J. Exp. Med. 213, 2527–2538 (2016).
Goldbach-Mansky, R., Alehashemi, S. & de Jesus, A. A. Emerging concepts and treatments in autoinflammatory interferonopathies and monogenic systemic lupus erythematosus. Nat. Rev. Rheumatol. 21, 22–45 (2025).
Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721–731 (2011).
Leandro, M. J., Edwards, J. C., Cambridge, G., Ehrenstein, M. R. & Isenberg, D. A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46, 2673–2677 (2002). This study provides first evidence for the safety and efficacy of B lymphocyte depletion therapy in SLE.
Looney, R. J. et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50, 2580–2589 (2004).
Ostendorf, L. et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N. Engl. J. Med. 383, 1149–1155 (2020). This study provides first evidence for the efficacy of plasma cell depletion therapy in SLE.
Furie, R. A. et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N. Engl. J. Med. 392, 1471–1483 (2025). This large trial confirms that antibody-mediated B cell depletion is an effective treatmet strategy in SLE.
Morand, E. et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 75, 242–252 (2023).
Furie, R. et al. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 69, 376–386 (2017).
Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382, 211–221 (2020). This trial confirms that therapeutic blockade of the type 1 interferon receptor is an effective treatment approach in SLE.
Morand, E., Merola, J. F., Tanaka, Y., Gladman, D. & Fleischmann, R. TYK2: an emerging therapeutic target in rheumatic disease. Nat. Rev. Rheumatol. 20, 232–240 (2024).
Luo, H., Tian, T., Hu, C. & Hao, F. Targeting the cGAS–STING pathway: emerging strategies and challenges for the treatment of inflammatory skin diseases. Front. Pharmacol. 16, 1597443 (2025).
Matziol, T., Talagayev, V., Weindl, G. & Wolber, G. Structure-guided approaches to modulate endosomal toll-like receptors TLR7, TLR8 and TLR9: advances, challenges and therapeutic promise. Drug Discov. Today 30, 104495 (2025).
Lama, L. et al. Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered interferon expression. Nat. Commun. 10, 2261 (2019).
Scally, S. W. et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J. Exp. Med. 210, 2569–2582 (2013).
Raychaudhuri, S. et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat. Genet. 44, 291–296 (2012).
Holers, V. M. et al. Rheumatoid arthritis and the mucosal origins hypothesis: external protection becomes internal destruction. Nat. Rev. Rheumatol. 14, 542–557 (2018).
Klareskog, L., Padyukov, L., Rönnelid, J. & Alfredsson, L. Genes, environment and immunity in the development of rheumatoid arthritis. Curr. Opin. Immunol. 18, 650–655 (2006).
Willemze, A., Trouw, L. A., Toes, R. E. & Huizinga, T. W. The influence of ACPA status and characteristics on the course of RA. Nat. Rev. Rheumatol. 8, 144–152 (2012).
He, Y. et al. A subset of antibodies targeting citrullinated proteins confers protection from rheumatoid arthritis. Nat. Commun. 14, 691 (2023).
Croft, A. P. et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 570, 246–251 (2019).
Sokolove, J., Zhao, X., Chandra, P. E. & Robinson, W. H. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcγ receptor. Arthritis Rheum. 63, 53–62 (2011).
Nielen, M. M. J. et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50, 380–386 (2004).
Alivernini, S., Firestein, G. S. & McInnes, I. B. The pathogenesis of rheumatoid arthritis. Immunity 55, 2255–2270 (2022).
Majka, D. S. et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann. Rheum. Dis. 67, 801–807 (2008).
Alivernini, S. et al. Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nat. Med. 26, 1295–1306 (2020). This study shows that presence of immune-modulatory synovial macrophages is associated with remission in patients with RA.
Culemann, S. et al. Locally renewing resident synovial macrophages provide a protective barrier for the joint. Nature 572, 670–675 (2019). This study identifies a population of resident synovial macrophages that maintain an anti-inflammatory barrier preventing spontaneous synovial inflammation.
Pap, T., Müller-Ladner, U., Gay, R. E. & Gay, S. Fibroblast biology: role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res. Ther. 2, 361 (2000).
Cowan, M. J. B., Davidson, S., Coles, M. & Buckley, C. D. The role of fibroblasts across inflammation and immunity. Annu. Rev. Pathol. https://doi.org/10.1146/annurev-pathmechdis-080624-105114 (2026).
Harre, U. et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J. Clin. Invest. 122, 1791–1802 (2012).
Schett, G. & Teitelbaum, S. L. Osteoclasts and arthritis. J. Bone Miner. Res. 24, 1142–1146 (2009).
Harre, U. et al. Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat. Commun. 6, 6651 (2015).
Burmester, G. R. & Pope, J. E. Novel treatment strategies in rheumatoid arthritis. Lancet 389, 2338–2348 (2017).
Edwards, J. C. W. & Cambridge, G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 40, 205–211 (2001).
Edwards, J. C. W. & Cambridge, G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 6, 394–403 (2006).
An, J., Marwaha, A. & Laxer, R. M. Autoinflammatory diseases: a review. J. Rheumatol. 51, 848–861 (2024).
Szekanecz, Z. et al. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat. Rev. Rheumatol. 17, 585–595 (2021).
Hoffman, H. M., Mueller, J. L., Broide, D. H., Wanderer, A. A. & Kolodner, R. D. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome. Nat. Genet. 29, 301–305 (2001). This study identifies mutations in the gene encoding for NLRP3 as causative for a group of inherited autoinflammatory diseases.
Broderick, L. & Hoffman, H. M. IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting. Nat. Rev. Rheumatol. 18, 448–463 (2022).
Lamas, A., Faria, R., Marinho, A. & Vasconcelos, C. The mosaic of systemic lupus erythematosus: from autoimmunity to autoinflammation and immunodeficiency and back. Autoimmun. Rev. 23, 103675 (2024).
Ombrello, M. J. et al. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc. Natl Acad. Sci. USA. 112, 15970–15975 (2015).
Nigrovic, P. A. Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis. Proc. Natl Acad. Sci. USA. 112, 15785–15786 (2015).
Beck, D. B. et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N. Engl. J. Med. 383, 2628–2638 (2020).This study identifies acquired somatic mutations in UBA1 as causative for VEXAS syndrome.
Torreggiani, S., Castellan, F. S., Aksentijevich, I. & Beck, D. B. Somatic mutations in autoinflammatory and autoimmune disease. Nat. Rev. Rheumatol. 20, 683–698 (2024).
Savola, P., Bhattacharya, D. & Huuhtanen, J. The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty’s syndrome. Semin. Hematol. 59, 123–130 (2022).
Pascart, T. et al. Calcium pyrophosphate deposition disease. Lancet Rheumatol. 6, e791–e804 (2024).
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006).
Pascual, V., Allantaz, F., Arce, E., Punaro, M. & Banchereau, J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201, 1479–1486 (2005).
Schlesinger, N. Anti-interleukin-1 therapy in the management of gout. Curr. Rheumatol. Rep. 16, 398 (2014).
Lachmann, H. J. et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360, 2416–2425 (2009). This study shows the clinical efficacy of IL-1 blockade as approach in the treatment of inherited autoinflammatory diseases.
Weber, A. N. R. et al. The expanding role of the NLRP3 inflammasome from periodic fevers to therapeutic targets. Nat. Immunol. 26, 1453–1466 (2025).
Coll, R. C. et al. A small molecule inhibitior of the NLRP3 inflammasome is a potential therapeutic for inflammatory diseases. Nat. Med. 21, 248–255 (2015).
Leung, Y. Y., Yao Hui, L. L. & Kraus, V. B. Colchicine–update on mechanisms of action and therapeutic uses. Semin. Arthritis Rheum. 45, 341–350 (2015).
Liu, Z. et al. Immunosenescence: molecular mechanisms and diseases. Signal Transduct. Target. Ther. https://doi.org/10.1038/s41392-023-01451-2 (2023).
Shaw, A. C., Goldstein, D. R. & Montgomery, R. R. Age-dependent dysregulation of innate immunity. Nat. Rev. Immunol. 13, 875–887 (2013).
Salvarani, C., Pipitone, N., Versari, A. & Hunder, G. G. Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat. Rev. Rheumatol. 8, 509–521 (2012).
Hiitola, E. et al. Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes. Sci. Adv. 11, eadt9846 (2025).
Wu, H., Wei, J., Yu, Y., Wang, N. & Tan, X. Clonal hematopoiesis of indeterminate potential and the risk of autoimmune diseases. J. Intern. Med. 297, 642–656 (2025).
Uchiyama, S. et al. Mosaic loss of chromosome Y characterises late-onset rheumatoid arthritis and contrasting associations of polygenic risk score based on age at onset. Ann. Rheum. Dis. 84, 1313–1323 (2025).
Shiomi, M. et al. Uncovering the new biology of giant cell arteritis to guide therapeutic strategies. J. Clin. Med. 14, 6350 (2025).
Petzinna, S. M. et al. AYLo study-elevated relapse risk and dysregulated proinflammatory signalling in giant cell arteritis patients with mosaic loss of the Y chromosome. Ann. Rheum. Dis. 84, 1900–1908 (2025).
Ji, J., Liu, X., Sundquist, K., Sundquist, J. & Hemminki, K. Cancer risk in patients hospitalized with polymyalgia rheumatica and giant cell arteritis: a follow-up study in Sweden. Rheumatology 49, 1158–1163 (2010).
Kim, H.-H. & Dixit, V. D. Metabolic regulation of immunological aging. Nat. Aging 5, 1425–1440 (2025).
Weyand, C. M. & Goronzy, J. J. Immune aging in rheumatoid arthritis. Arthritis Rheumatol. 77, 792–804 (2025).
Zheng, Y., Liu, Q., Goronzy, J. J. & Weyand, C. M. Immune aging—a mechanism in autoimmune disease. Semin. Immunol. 69, 101814 (2023).
Shive, C. & Pandiyan, P. Inflammation, immune senescence, and dysregulated immune regulation in the elderly. Front. Aging 3, 840827 (2022).
Bonelli, M. et al. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial. Ann. Rheum. Dis. 81, 838–844 (2022).
Tomelleri, A. et al. Disease stratification in GCA and PMR: state of the art and future perspectives. Nat. Rev. Rheumatol. 19, 446–459 (2023).
Stone, J. H. et al. Trial of tocilizumab in giant-cell arteritis. N. Engl. J. Med. 377, 317–328 (2017).
Queiro, R., Morante, I., Cabezas, I. & Acasuso, B. HLA-B27 and psoriatic disease: a modern view of an old relationship. Rheumatology 55, 221–229 (2016).
Brewerton, D. A. et al. Ankylosing spondylitis and HL-A27. Lancet 1, 904–907 (1973).
Yang, X. et al. Autoimmunity-associated T cell receptors recognize HLA-B*27-bound peptides. Nature 612, 771–777 (2022). This study identifies autoreactive T cell receptors that cross-react to self- and microbial-derived peptides presented by HLA-B27.
Paley, M. A. et al. Mucosal signatures of pathogenic T cells in HLA-B*27+ anterior uveitis and axial spondyloarthritis. JCI Insight 9, e174776 (2024).
McGonagle, D., Gibbon, W. & Emery, P. Classification of inflammatory arthritis by enthesitis. Lancet 352, 1137–1140 (1998).
McGonagle, D. et al. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum. 41, 694–700 (1998). This study identifies enthesitis as common hallmark of spondylarthropathies.
Benjamin, M. et al. Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for bone involvement in the HLA-B27-associated spondylarthritides and allied disorders. Arthritis Rheum. 56, 224–233 (2007).
Sherlock, J. P. et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+CD3+CD4−CD8− entheseal resident T cells. Nat. Med. 18, 1069–1076 (2012).
Bridgewood, C., Sharif, K., Sherlock, J., Watad, A. & McGonagle, D. Interleukin-23 pathway at the enthesis: the emerging story of enthesitis in spondyloarthropathy. Immunol. Rev. 294, 27–47 (2020).
Ono, T. et al. IL-17-producing γδ T cells enhance bone regeneration. Nat. Commun. 7, 10928 (2016).
Ciccia, F. et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum. 60, 955–965 (2009).
Jo, S. et al. IL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis. Arthritis Res. Ther. 20, 115 (2018).
Łukasik, Z., Gracey, E., Venken, K., Ritchlin, C. & Elewaut, D. Crossing the boundaries: IL-23 and its role in linking inflammation of the skin, gut and joints. Rheumatology 60, iv16–iv27 (2021).
Wellcome Trust Case Control Consortium & The Australo-Anglo-American Spondylitis Consortium (TASC). Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet. 39, 1329–1337 (2007).
Rahman, P. et al. Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum. 58, 1020–1025 (2008).
Villalpando-Vargas, F. V. et al. Association between IL-17A, IL-17F and IL-17RA gene polymorphisms and susceptibility to psoriasis and psoriatic arthritis: a meta-analysis. Inflamm. Res. 70, 1201–1210 (2021).
Deodhar, A. et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395, 1115–1125 (2020).
Tsukazaki, H. & Kaito, T. The role of the IL-23/IL-17 pathway in the pathogenesis of spondyloarthritis. Int. J. Mol. Sci. 21, 6401 (2020).
Baeten, D. et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N. Engl. J. Med. 373, 2534–2548 (2015).
Hotamisligil, G. S. Inflammation, metaflammation and immunometabolic disorders. Nature 542, 177–185 (2017).
Haberman, R. H., Ogdie, A., Merola, J. F., Scher, J. U. & Eder, L. The obesity–inflammation axis in psoriatic disease: mechanisms and therapeutic strategies. Nat. Rev. Rheumatol. 22, 151–164 (2026).
Merola, J. F. et al. Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: results from a randomized clinical trial. Arthrits Rheum. https://doi.org/10.1002/art.70134 (2026).
Donath, M. Y. & Drucker, D. J. Obesity, diabetes, and inflammation: pathophysiology and clinical implications. Immunity 58, 2373–2382 (2025).
Gokce, M. et al. The impact of liraglutide, a GLP-1 receptor agonist, on high glucose-induced inflammation, apoptosis, oxidative stress, and NLRP3 signaling. Cell Biochem. Biophys. 83, 3619–3632 (2025).
Hench, P. S., Kendall, E. C., Slocumb, C. H. & Polley, H. F. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocortical hormone in arthritis: preliminary report. Ann. Rheum. Dis. 8, 97–104 (1949).
Eiers, A.-K., Vettorazzi, S. & Tuckermann, J. P. Journey through discovery of 75 years glucocorticoids: evolution of our knowledge of glucocorticoid receptor mechanisms in rheumatic diseases. Ann. Rheum. Dis. 83, 1603–1613 (2024).
Auger, J.-P. et al. Metabolic rewiring promotes anti-inflammatory effects of glucocorticoids. Nature 629, 184–192 (2024). This study shows that the anti-inflammatory effects of glucocorticoids are linked to a mitochondrial reprogramming of immune cells.
Furie, R. A. et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology 60, 5397–5407 (2021).
Moreland, L. W. et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 46, 1470–1479 (2002).
Ruderman, E. M. Overview of safety of non-biologic and biologic DMARDs. Rheumatology 51, vi37–vi43 (2012).
van der Heijde, D. et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann. Rheum. Dis. 82, 515–526 (2023).
McInnes, I. B. et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet 401, 25–37 (2023).
Dömling, A. & Holak, T. A. Balinatunfib: a clinical oral small molecule TNFα inhibitor. ChemMedChem. 20, e202500258 (2025).
Bissonnette, R. et al. Oral icotrokinra for plaque psoriasis in adults and adolescents. N. Engl. J. Med. 393, 1784–1795 (2025).
Ramirez-Perez, S. et al. MyD88 dimerization inhibitor ST2825 targets the aggressiveness of synovial fibroblasts in rheumatoid arthritis patients. Arthritis Res. Ther. 25, 180 (2023).
Ringheim, G. E., Wampole, M. & Oberoi, K. Bruton’s tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures. Front. Immunol. 12, 662223 (2021).
Edmondson, S. D. Discovery of the first clinical protein degrader for the treatment of autoimmune indications: orally bioavailable and selective IRAK4 degrader KT-474. J. Med. Chem. 67, 18017–18021 (2024).
Brenke, J. K. et al. Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity. J. Biol. Chem. 293, 13191–13203 (2018).
Jimenez-Sanchez, S., Maksoud, R., Eaton-Fitch, N., Marshall-Gradisnik, S. & Broadley, S. A. The role of alemtuzumab in the development of secondary autoimmunity in multiple sclerosis: a systematic review. J. Neuroinflammation 21, 281 (2024).
Tuttle, J. et al. A phase 2 trial of peresolimab for adults with rheumatoid arthritis. N. Engl. J. Med. 388, 1853–1862 (2023).
Britanova, O. V. et al. Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitis. Nat. Med. 29, 2731–2736 (2023).
Furie, R. A. et al. Efficacy and safety of obinutuzumab in active systemic lupus erythematosus. N. Engl. J. Med. 392, 1471–1483 (2025).
Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 64, 1215–1226 (2012).
Merrill, J. T. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222–233 (2010).
Kamburova, E. G. et al. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function. Am. J. Transplant. 13, 1503–1511 (2013).
Alexander, T. & Greco, R. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 57, 1055–1062 (2022).
van Laar, J. M. et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311, 2490–2498 (2014).
Mougiakakos, D. et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N. Engl. J. Med. 385, 567–569 (2021). The first case report demonstrating the efficacy of CD19 CAR-T cells in a patient with refractory SLE.
Alexander, T., Krönke, J., Cheng, Q., Keller, U. & Krönke, G. Teclistamab-induced remission in refractory systemic lupus erythematosus. N. Engl. J. Med. 391, 864–866 (2024).
Tur, C. et al. Effects of different B-cell-depleting strategies on the lymphatic tissue. Ann. Rheum. Dis. 84, 2065–2074 (2025).
Siegert, E. et al. Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation. Ann. Rheum. Dis. 84, 653–656 (2025).
Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124–2132 (2022).
Hagen, M. et al. BCMA-targeted T-cell-engager therapy for autoimmune disease. N. Engl. J. Med. 391, 867–869 (2024).
Minopoulou, I. et al. Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis. Ann. Rheum. Dis. 84, e4–e7 (2025).
Wilhelm, A. et al. Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE. JCI Insight 9, e179433 (2024).
Müller, F. et al. CD19 CAR T-cell therapy in autoimmune disease - a case series with Follow-up. N. Engl. J. Med. 390, 687–700 (2024). A case series illustrating the capacity of CD19 CAR-T cells to induce a sustained drug free remission in SLE.
Müller, F. et al. CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial. Nat. Med. https://doi.org/10.1038/s41591-025-04185-6 (2026).
Junt, T. et al. Defining immune reset: achieving sustained remission in autoimmune diseases. Nat. Rev. Immunol. 25, 528–541 (2025).
Albach, F. N. et al. CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial. Nat. Med. 32, 3862–3873 (2026).
Ellebrecht, C. T. et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353, 179–184 (2016).
Oh, S. et al. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat. Biotechnol. 41, 1229–1238 (2023).
来源:Nature 综合主刊 · nature.com